Page 36 - Recent Highlights News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results Full year 2020 revenues of $5.4 million compared to $2.3 million in 2019 News provided by Share this article Share this article REDWOOD CITY, Calif., March 15, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its fourth quarter and full year 2020 financial results. "Last year we achieved many important milestones and obje...

Published: Mar 11, 2021 New Drug Application (“NDA”) submitted to the U.S. Food and Drug Administration (“FDA”) for BXCL501 for the acute treatment of schizophrenia and bipolar disorder related agitation TRANQUILITY achieved primary and secondary endpoints with both doses of BXCL501; End of Phase 2 meeting with the FDA planned for Q2 2021 RELEASE trial on track to report topline results in Q1 2021 Topline results from two ongoing trials with BXCL701 in aggressive forms of prostate cancer and advanced solid tumors are expected in mid-2021 Company to host conference call today at ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. BioXcel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides ... BioXcel TherapeuticsMarch 11, 2021 GMT New Drug Application (“NDA”) submitted to the U.S. Food and Drug Administration (“FDA”) for BXCL501 for the acute treatment of schizophrenia and bipolar disorder related agitation TRANQUILITY achieved primary and secondary endpoints with both doses of BXCL501; End of Phase 2 meeting with the FDA planned for Q2 2021 RELEASE trial on track to report topline ...

Champions Oncology, Inc.: Champions Oncology Reports Record Quarterly Revenue of $10.8 Million HACKENSACK, NJ / ACCESSWIRE / March 11, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider engaged in transforming drug discovery and development through data-driven research strategies and innovative pharmacology, biomarker and data platforms, today announced its financial results for the third fiscal quarter ended January 31, 2021. Third Quarter and Recent Highlights: Delivered record quarterly revenue of $10.8 million, an increase of 20% year ov...

19% Sequential Increase in Total Revenue Tigereye Drives 38% Sequential Growth in Image-Guided CTO Revenue REDWOOD CITY, CA / ACCESSWIRE / March 11, 2021 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage